2025-02-22 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Overview:** Johnson & Johnson is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

**1. Performance Comparison & Divergence:**

JNJ's cumulative return (38.26%) significantly underperformed the S&P 500 (VOO) with a cumulative return of 118.31%. The difference is -80.1%, placing it at the 16.2nd percentile of its historical range relative to the S&P 500 (-99.0% to 17.7%).  This indicates JNJ's consistent underperformance compared to the broader market.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 277.3 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.1 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 305.7 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 338.8 |
| 2019-2021  | 28.0% | 7.9% | -43.0% | 0.4 | 377.6 |
| 2020-2022  | 17.0% | 7.9% | 9.0% | 0.4 | 400.1 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 365.8 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 348.2 |
| 2023-2025  | -1.0% | 8.0% | -60.0% | 0.2 | 390.8 |

The provided alpha values show inconsistent outperformance relative to the market (positive alpha indicating outperformance). Beta values generally hover around 0.0 to 0.7, suggesting lower than average market volatility.  However, recent years show a decline in CAGR and negative alpha.

**2. Recent Price Movement:**

* **Closing Price:** $162.30
* **5-day Moving Average:** $158.20
* **20-day Moving Average:** $154.34
* **60-day Moving Average:** $149.65

The price is above all three moving averages, suggesting a short-term uptrend.  The recent price change of $1.64 represents a positive price movement (approximately 1% increase).


**3. Technical Indicators & Expected Return:**

* **RSI:** 75.24 (Overbought territory, suggesting potential short-term correction)
* **PPO:** 0.39 (Positive, indicating bullish momentum)
* **Delta_Previous_Relative_Divergence:** +6.7 (Short-term upward momentum)
* **Expected Return (2+ years):** -146.2% (This significantly negative expected return relative to the S&P 500 is a major concern and requires further investigation into the model used to generate this figure).


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-10-23 | 1.12 | $22.47B       |
| 2024-07-25 | 1.95 | $22.45B       |
| 2024-05-01 | 1.35 | $21.38B       |
| 2024-02-16 | 1.68 | $21.39B       |
| 2023-10-27 | 10.32 | $21.35B       |

EPS shows significant volatility.  The exceptionally high EPS in October 2023 is an outlier that needs further investigation. Revenue remains relatively stable around $21-$22.5B.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |
| 2023-12-31 | $21.39B  | 68.23%        |

Revenue is relatively consistent. Profit margins are high and stable, averaging around 69%.


**Capital and Profitability:**

| Quarter | Equity    | ROE   |
|---------|-----------|-------|
| 2024-12-31 | $71.49B  | 4.80% |
| 2024-09-30 | $70.16B  | 3.84% |
| 2024-06-30 | $71.54B  | 6.55% |
| 2024-03-31 | $70.02B  | 4.65% |
| 2023-12-31 | $68.77B  | 5.89% |

Equity is relatively stable. ROE fluctuates but remains reasonably healthy.


**6. Overall Analysis:**

JNJ has shown consistent underperformance relative to the S&P 500 over the period analyzed.  While the company shows strong and stable profit margins and relatively consistent revenue, the recent earnings data reveals EPS volatility. The significantly negative long-term expected return (-146.2%) compared to the S&P 500 is a major red flag and needs further scrutiny.  The overbought RSI suggests potential near-term price correction.  Before investing, a thorough examination of the outlier EPS figure in Q4 2023 and the methodology behind the negative long-term expected return is crucial.  The relatively stable financials are positive but the market underperformance is a serious concern.
